Cilostazol included dual antiplatelet therapy reduces stroke recurrence

According to late-breaking science presented at the American Stroke Association's International Stroke Conference 2019, Stroke survivors taking a combination of the blood thinner cilostazol with aspirin or clopidogrel had a lower risk of ischemic stroke recurrence than those who received aspirin or clopidogrel alone.

The treatment failure by DAPT has occurred due to heterogeneity in the response of individual patients to aspirin or clopidogrel. Moreover, resistance to aspirin or clopidogrel has been seen clinically, and there is a relatively high prevalence of clopidogrel resistance in Asia.

Although aspirin and clopidogrel have been shown to reduce early recurrence of ischemic stroke, the benefits seem to be short and was offset by a risk of major bleeding in long-term usage, said lead author Kazunori Toyoda, M.D., Ph.D., Deputy Director General of the Hospital, National Cerebral and Cardiovascular Center in Suita, Osaka, Japan.

Since cilostazol has been shown to prevent stroke recurrence without increasing serious bleeding as compared to aspirin, researchers studied if dual antiplatelet therapy involving cilostazol would be safe and fit for long-term usage.

In a multicenter open-label, a parallel-group trial called The Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com), high-risk patients were randomly assigned to receive aspirin or clopidogrel alone, or a combination of cilostazol with aspirin or clopidogrel at 292 sites in Japan over about four years. The study included 1,839 patients, including 756 taking aspirin and 1,083 taking clopidogrel. They had suffered an ischemic stroke up to six months earlier.

Researchers found:

• The risk of a recurrence of ischemic stroke in high-risk patients was less common with long-term dual medication with cilostazol plus aspirin or clopidogrel compared to long-term therapy with aspirin or clopidogrel alone.


• Both approaches had a similar risk of major bleeding.

The study was funded by Otsuka Pharmaceutical Co. Ltd.